{
  "docId": "019de075-7d9e-72c3-b72b-f46b67767727",
  "docSlug": "53c1bfc711678d7524a7d4316a5473e9",
  "documentTitle": "Chimerix | Investor Presentation Deck | 43 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 36,
  "pageCount": 43,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Uses a visual icon array to represent survival rates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-7d9e-72c3-b72b-f46b67767727/36",
  "deckHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727",
  "deckJsonHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727.json",
  "deckAnchorHref": "/decks/019de075-7d9e-72c3-b72b-f46b67767727#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.07,
        "y": 0.5
      },
      "kind": "image",
      "text": "1 out of 20 icon array",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abae2006-4176-42d0-9aaa-2a8962a2cf2a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.62
      },
      "kind": "list",
      "text": "Chimerix retains global operational rights to ONC206",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20b3a068-a478-4773-8999-eef680908da6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.03,
        "y": 0.25
      },
      "kind": "list",
      "text": "GBM is a rapidly progressive disease with low survival rates, few drug approvals last 25 years: Temozolomide (TMZ) approved 1999; Bevacizumab approved 2009",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60b41ea7-9777-42e9-92ae-c60a94a35004",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.9,
        "x": 0.03,
        "y": 0.68
      },
      "kind": "list",
      "text": "Worldwide market opportunity exceeds $2Bn: TMZ revenue peaked at ~$1.4B in 2009 (>$2.5Bn adj); New GBM therapy: 50% penetration exceeds $2Bn",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6870c44e-6604-4caa-8346-db1d2068af15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.41
      },
      "kind": "list",
      "text": "Existing therapies rarely offer durable effect: 3-year survival from diagnosis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed3916d5-5935-4713-9d3a-ddc9db6b9e73",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.1,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "1 wjso.biomedcentral.com/articles/10.1186/1477-7819-10-220 2 Royalties and milestones are owed to legacy Oncoceutics shareholders by virtue of the 2021 merger agreement",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c28cad92-9a89-4435-806f-96f6b131d757",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.76,
        "x": 0.12,
        "y": 0.06
      },
      "kind": "title",
      "text": "~30,000 new cases of GBM annually in the top 7 markets; >$2Bn market opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d0cbcfe-fa41-45f2-8d26-d46afba8fb02",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 43,
      "from": 16,
      "beatId": "159a3ef0-298f-499a-afc1-676405bbdbe9",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents ONC201 as a solution, including its mechanism of action, market opportunity, and development plans",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 43,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "cb576a48-1f93-4d7c-8d9b-075787961712",
      "evidence": "The deck presents ONC201's potential for efficacy and market opportunity",
      "position": 1,
      "objective": "Can ONC201 be a quick win and a big bet for Chimerix?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}